NCT02656381

Uveitis/Intraocular Inflammatory Disease Biobank (iBank)

Completed Last updated 6 April 2026

What this trial tests

trial in Uveitis in 343 participants. Completed in 4 May 2023.

Timeline

26 July 2016

Primary endpoint
4 May 2023

4 May 2023

Quick facts

Lead sponsor	National Eye Institute (NEI)
Status	Completed
Study type	OBSERVATIONAL
Enrollment	343
Start date	26 July 2016
Primary completion	4 May 2023
Estimated completion	4 May 2023
Sites	1 location across United States

Conditions studied

• Uveitis — all drugs for Uveitis →

Sponsor

National Eye Institute (NEI)

Who can join

Adults 8 to 100, any sex, with Uveitis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Background:

Uveitis is a serious eye disease that can cause vision loss. Treatment sometimes causes serious side effects or does not work. Researchers want to learn more about uveitis and why some people develop it.

Objective:

To learn clinical and genetic factors that may make people develop uveitis and influence how they respond to treatment.

Eligibility:

People ages 8 and older who have uveitis, scleritis, inflammatory eye disease, or a disease related to eye inflammation

INCLUSION CRITERIA FOR COVID-19 COHORT:

Participants with COVID-19 will be eligible if they:

1. Have a diagnosis of COVID-19 confirmed by a nasaopharyngeal swab (or another confirmative test) within less than or equal to 3 days prior, with symptoms of any severity.
2. Are able to give verbal consent.
3. Are 16 years of age or older.

EXCLUSION CRITERIA FOR COVID-19 COHORT:

Participants with COVID-19 will not be eligible if they:

1. Use regular prescription eye drops on the day of sampling.
2. Current use of antiviral medications.

Design:

Participants will be screened with:

Medical history

Physical exam

Eye exam

Participation lasts up to 10 years. The clinic visit schedule varies depending on participants eye disease:

Baseline visit with annual follow-ups

Baseline visit, visits at months 3 and 6, and annual follow-ups

Another schedule set by the researcher

Depending on participants eye disease, tests during each visit could include:

Fluorescein angiography or indocyanine green angiography: Dye is injected through a needle in the arm

and flows through the blood vessels in the eye. A camera takes pictures of the eye.

Electroretinography: Participants sit in the dark with their eyes patched.

After 30 minutes, numbing drops and contact lenses are put in the eyes. Then, the retina is stimulated with flashing lights.

Perimetry: Participants look into a bowl or lens and press a button when they see a light.

Conjunctival or corneal biopsy, or skin biopsy: A small piece of tissue is removed.

Anterior chamber tap: A needle enters the eye to remove fluid.

Blood and urine tests

Saliva, stool, hair, or tear samples

Cotton swab of the inside of the cheek.

During the study, participants may need immunosuppressive treatment, such as drugs or injections in or around the eyes depending on their disease.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

1. A novel role for lipoxin A<sub>4</sub> in driving a lymph node-eye axis that controls autoimmunity to the neuroretina.
   Wei J, Mattapallil MJ, Horai R, Jittayasothorn Y, et al · · 2020 · cited 16× · PMID 32118582 · DOI 10.7554/elife.51102
2. Automated Detection of Vascular Leakage in Fluorescein Angiography - A Proof of Concept.
   Young LH, Kim J, Yakin M, Lin H, et al · · 2022 · cited 9× · PMID 35877095 · DOI 10.1167/tvst.11.7.19
3. Single-cell profiling identifies a CD8<sup>bright</sup> CD244<sup>bright</sup> Natural Killer cell subset that reflects disease activity in HLA-A29-positive birdshot chorioretinopathy.
   Nath PR, Maclean M, Nagarajan V, Lee JW, et al · · 2024 · cited 8× · PMID 39085199 · DOI 10.1038/s41467-024-50472-0